期刊文献+

急性心肌梗死伴阵发房颤的临床研究 被引量:4

A Clinical Study of Acute Myocardial Infarction with Paroxysmal Atrial Fibrillation
下载PDF
导出
摘要 目的:探讨急性心肌梗死(AMI)合并阵发心房颤动(AF)患者AF复发的影响因素。方法:将120例AMI伴阵发AF患者,在随访1年期间依有无AF复发分为复发组和窦性心律(窦律)组,比较2组一般资料、病史、血清C反应蛋白(CRP)水平、低密度脂蛋白胆固醇(LDL-C)水平、左房内径(LAD)、左室射血分数(LVEF),评价心功能,同时比较不同治疗方法患者间的AF复发率。结果:复发组年龄、心功能分级、患高血压和前壁心肌梗死高于或多于窦律组,LVEF低于窦律组,LAD大于窦律组(P<0.05或P<0.01)。溶栓再通患者AF复发率低于未溶或未再通患者,服用他汀患者AF复发率低于未服用他汀患者(均P<0.05)。高龄、高血压病、前壁梗死、高CRP水平、LAD增大和心功能减退是AF复发的危险因素;溶栓再通、服用他汀是抑制AF复发的保护性因素(P<0.05或P<0.01)。结论:高龄、高血压、前壁梗死、LAD增大、心功能减退促使AF的复发;早期血运重建、应用他汀类药物可抑制AF复发。 Objective:To investigate the clinical factors influencing the atrial fibrillation(AF) recurrence in patients with acute myocardial infarction(AMI) combined paroxysmal AF.Methods:One hundred and twenty patients with AMI and AF were divided into two groups,the recurrence group and the normal sinus rhythm(NSR) group based on with or without the AF recurrence during the one year follow-up.The general information and medical history were compared between the patients of the two groups.At the end of the one-year follow-up,the levels of C-reactive protein(CRP),low-density lipoprotein(LDL-C),left atrial diameter(LAD) and left ventricular ejection fraction(LVEF) were detected in patients.The recurrence ratios of AF were compared in patients with different treatment methods.Results:The average age,cardiac function,hypertension and anterior myocardial infarction were significantly higher in patients of recurrence group than those of NSR group(P 0.01).The value of LVEF was lower,LAD was larger in patients of NSR group than those of recurrence group(P 0.05 or P 0.01).There was a significantly lower recurrence rate of AF in patients with successful intravenous thrombolysis and with treatment of statins compared with that of patients without the application of intravenous thrombolysis,failure to reperfusion or without treatment of statins(P 0.01).Binary logistic analysis showed that age,hypertension,anterior myocardial infarction,high level of CRP,LAD enlargement and cardiac dysfunction increased the risk for the recurrences of AF(P 0.05 or P 0.01),and that revascularization and treatment with statins were the preventive measures against the recurrence of AF(P 0.05).Conclusion:Precipitating factors for the recurrence of AF included senior age,hypertension,anterior wall infarction,LAD enlargement and cardiac dysfunction.Therefore,early revascularization and treatment with statins are effective measures against the recurrence of AF.
出处 《天津医药》 CAS 北大核心 2010年第12期1053-1055,共3页 Tianjin Medical Journal
关键词 心肌梗死 急性病 心房颤动 C反应蛋白质 阿托伐他汀 LOGISTIC模型 myocardial infarction acute disease atrial fibrillation C-reactive protein atorvastatin logistic models
  • 相关文献

参考文献7

  • 1Kannel WB,Abbott RD,Savage DD,et al.Epidemiologic femures of chronic atrial fibrillation:the Framingham study[J].N Engl J Med,1982,306(17):1018-1022.
  • 2赵良平,吕安康,沈卫峰.C反应蛋白与心房颤动[J].临床内科杂志,2009,26(1):8-11. 被引量:2
  • 3Watanabe T,Takeishi Y,Hirono O,et al.C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation[J].Heart Vessels,2005,20(2):45-49.
  • 4Sata N,Hamada N,Horinouchi T,et al.C-reactive protein and atril fibrillation:Is inflammation a consequence or a cause of atril fibrillation[J] ?Jpn Heart J,2004,45(3):441-445.
  • 5Kallergis EM,Manios EG,Kanoupakis EM,et al.The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atril fibrillation[J].Heart,2008,94(2):200-204.
  • 6袁志波.他汀类药物对高血压伴房颤患者炎性标志物及血栓素的影响[J].临床和实验医学杂志,2008,7(9):86-87. 被引量:3
  • 7Pedersen TR,Faergeman O,Kastelein JJ,et al.For the incremental Decrease in End Points ThrouIgh Aggressive lipid lowering Study Group.High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardiol infarction.The IDEAL Study:a randomized controlled atril[J].JAMA,2005,294(19):2437-2445.

二级参考文献34

  • 1汪洪,汪宪平.原发性高血压患者血浆血栓素B_2检测的临床意义[J].放射免疫学杂志,2005,18(5):350-351. 被引量:12
  • 2Oliver Adam, Hans-Ruprecht Neuberger, Michael Bo hm, et al. Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors. Circulation ,2008,118 : 1285-1293.
  • 3Boos CJ,Anderson RA,Lip G. Is atrial fibrillation an inflammatory dis- order? European Heart Journal ,2006,27 : 136-149.
  • 4Acevedo M, Cobalan RL, Perez L, et al. C-reactive protein in atrial fibril- lation:evidence for the presence of inflammation in the genesis and perpetuation of the arrhythmia. J Am Coll Cardiol,2003 ,41:1089-1091.
  • 5Zysko D, Gajek J, Mazurek W. The contribution of inflammatory process in pathogenesis and natural history of atrial fibrillation. Pol Merkur Lekarski ,2005,18:227-228.
  • 6Aronson D, Boulos M, Suleiman A, et al. Relation of C-reactive protein and new-onset atrial fibrillation in patients with acute myocardial infarction. Am J Cardiol,2007 ,100 :753-757.
  • 7Ucar HI, Tok M, Atalar E, et al. Predictive significance of plasma levels of interleukin-6 and high-sensitivity C-reactive protein in atrial fibrillation after coronary artery bypass surgery. Heart Surg Forum,2007,10: E131-135.
  • 8Loricchio ML, Cianfrocca C, Pasceri V, et al. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol,2007,99 : 1421-1424.
  • 9Fujiki A, Sakamoto T, Nishida K, et al. Relation of inedeukin-6 and C-reactive protein levels to sinus maintenance after pharmacological cardioversion in persistent atrial fibrillation. J Cardiovasc Pharmacol, 2007,50:264-266.
  • 10Tong Liu, Guangping Li, Lijian Li, et al. Association Between C-Reactive Protein and Recurrence of Atrial Fibrillation After Successful Electrical Cardioversion A Meta-Analysis. JACC,2007,49:1642 - 1648.

共引文献3

同被引文献32

  • 1高明字.急性脑血管意外与急性心肌梗死[J].中国水电医学,2010,12(2):2246-2248.
  • 2Hanna I R, Heeke B, Bush H, et al. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction [J]. Heart Rhythm, 2007,3(8) :881.
  • 3Aschenbrenner D S. Factors that decrease the effectiveness of cloidogrel [J]. Am J Nurs, 2009,109(6) :66-67.
  • 4Derry S, LokeY K. Risk of gastrointestinal haemorrhage with longer use of aspirin : Meta analysis [ J ]. BMJ, 2000,321 (7270) : 1183-1187.
  • 5Juurlink D N, Comes T, Ko D T, et al. A oulation-based study of the drug interaction between rotonum inhibitors and cloidogrel [J]. CMAJ, 2009,180(7) :713-718.
  • 6Sata N, Hamada N, Horinouchi T, et al. C-reactive protein and atril fibrillation: Is inflammation a consequence or a cause of atril fibrillation [J]. JPN Heart J, 2004,45(3):441-445.
  • 7Kallergis E M, Manios E G, Kanoupakis E M, et al. The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atril fibrillation [ J ]. Heart, 2008,94 (2) : 200-204.
  • 8Geisler T, Schaeffeler E, Dippon J, et al. CYP2C 19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation [J]. Pharmacogenomics, 2008,9(9) : 1251-1259.
  • 9Pedersen T R, Faergeman O, Kastelein J J, et al. For the incremental Decrease in End Points Through Aggressive lipid lowering Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardiol infarction. The IDEAL Study: a randomized controlled atril [J]. JAMA, 2005,294 (19) : 2437-2445.
  • 10Rathore SS,Berger AK, Weinfurt KP,et al. Acute myocardial infarc-tion complicated by atrial fibrillation in the elderly prevalence andoutcome[ J]. Circulation,2000 ,101 (9) :969 - 974.

引证文献4

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部